Tonix Pharmaceuticals Holding Corp. TNXP
9.86
0.16
1.65%
as of 25 Sep
- Market cap
- $166.4M
- P/E
- 0.0×
Follow TNXP
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
7.29 | 10.74 | 10.14 | 20.93 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.02) | (4.45) | (3.35) | (7.49) | |
P/B ratio |
0.95 | 0.83 | 0.54 | 0.93 | |
Price to Tangible BV |
0.96 | 0.83 | 0.54 | 0.93 | |
EV/Sales |
1.50 | 0.60 | (5.13) | 3.20 | |
EV/EBITDA |
0.00 | 0.00 | 0.54 | 0.00 | |
EV/Operating CF |
(0.28) | (0.08) | 0.67 | (0.44) | |
EV/FCF |
(0.28) | (0.08) | 0.65 | (0.43) | |
Quick Ratio |
6.11 | 6.55 | 6.94 | 9.20 | |
Current Ratio |
6.61 | 6.99 | 7.42 | 9.89 | |
Net Debt/EBITDA |
4.20 | 4.53 | 4.34 | 5.83 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.13 | 0.08 | 0.06 | 0.06 | |
Operating CF/Net income |
1.04 | 1.05 | 0.85 | 0.90 | |
Capex/Depreciation |
(0.95) | (3.05) | (3.84) | (2.09) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
143.36% | 264.80% | 314.30% | 282.34% | |
Selling, General and Administrative Expense of Revenue |
265.50% | 416.17% | 661.91% | 781.19% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
16.66% | 28.64% | 33.19% | 58.45% | |
Graham Net Nets |
0.81 | 0.94 | 1.48 | 0.87 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(103.81%) | (106.66%) | (93.32%) | (83.03%) | |
Free Cash Flow Yield |
(74.49%) | (69.31%) | (77.63%) | (35.40%) | |
Revenue per Share |
0.81 | 0.50 | 0.63 | 0.37 | |
Operating CF per Share |
(2.54) | (3.09) | (4.66) | (3.23) | |
Capex per Share |
(0.04) | (0.12) | (0.22) | (0.11) | |
Free Cash Flow per Share |
(2.57) | (3.21) | (4.88) | (3.33) | |
Cash per Share |
10.59 | 13.53 | 24.40 | 21.30 | |
Shareholders Equity per Share |
13.36 | 16.57 | 28.80 | 25.90 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
13.36 | 16.57 | 28.80 | 25.90 | |
Free Cash Flow |
(42.83) | (44.01) | (41.52) | (29.74) | |
Working Capital |
172.65 | 177.52 | 198.04 | 187.04 | |
Capital Expenditures |
(0.59) | (1.69) | (1.87) | (0.96) | |
Net Current Asset Value |
171.63 | 176.39 | 196.86 | 186.77 | |
EV/EBIT |
0.00 | 0.00 | 0.53 | 0.00 | |
Capex to Sales |
0.04 | 0.25 | 0.35 | 0.29 | |
Net Profit Margin |
(299.41%) | (584.38%) | (870.32%) | (972.95%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.06 | 6.07 | 4.98 | 3.75 | |
Average Payables |
8.42 | 6.92 | 6.33 | 6.24 | |
Average Inventory |
5.33 | 5.89 | 7.21 | 6.83 | |
Average Assets |
220.72 | 225.39 | 220.03 | 173.71 | |
Average Common Equity |
195.14 | 203.77 | 192.35 | 152.68 |
Columns are period end dates